TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22940889
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and intravenous placebo pre‐ and postoperatively
Study: 20208358
Drug: D-psicose (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-psicose (5 g)
Study: 20208358
Drug: D-glucose (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-glucose (5 g)
Study: 18975521
Drug: Oral verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral verapamil 40 mg every 8 hours
Study: 10397379
Drug: Atovaquone and
Normalized name: Atovaquone and proguanil only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atovaquone and proguanil (1000 mg and 400 mg respectively, administered orally at 24-hour intervals for 3 doses)
Study: 10397379
Drug: Pyrimethamine/sulfadoxine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrimethamine/sulfadoxine (75 mg/1500 mg administered orally as a single dose)
Study: 6538844
Drug: Cimoxatone, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimoxatone, 40 mg oral dose
Study: 12225492
Drug: Short-term and
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term and long-term treatment
Study: 29486514
Drug: ACE-083 (50-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE-083 (50-200 mg) administered unilaterally into rectus femoris (RF) or tibialis anterior (TA) muscles as 1 or 2 doses 3 weeks apart
Study: 20040005
Drug: XIENCE V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: XIENCE V everolimus eluting coronary stent system (everolimus doses ranging from 53 to 181 microg)
Study: 16150687
Drug: Child Dissociative
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child Dissociative Checklist (CDC) administered to children with abuse histories
Study: 16150687
Drug: Child Dissociative
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child Dissociative Checklist (CDC) administered to children with ADHD
Study: 16150687
Drug: Child Dissociative
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child Dissociative Checklist (CDC) administered to control group (no abuse or psychiatric record)
Study: 10027428
Drug: Spiros Inhalation
Normalized name: 4-Deoxo-3,4-(2-spiro(N-isobutyl-4-piperidyl)-2,5-dihydro-1H-imidazo)-rifamycin S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spiros Inhalation System (Dura Pharmaceuticals; 108 microg/actuation of albuterol sulfate equivalent to 90 microg of albuterol base)
Study: 10027428
Drug: albuterol metered-dose
Normalized name: albuterol Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: albuterol metered-dose inhaler (MDI; 90 microg/actuation of albuterol)
Study: 8622105
Drug: Isepamicin 15
Normalized name: isepamicin
DrugBank: Isepamicin (DB13540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isepamicin 15 mg/kg once daily (n = 15)
Study: 8622105
Drug: Isepamicin 8
Normalized name: isepamicin
DrugBank: Isepamicin (DB13540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isepamicin 8 mg/kg once daily (n = 93)
Study: 8622105
Drug: Amikacin 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin 7.5 mg/kg twice daily (n = 18)
Study: 8622105
Drug: Amikacin 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin 7.5 mg/kg twice daily (n = 47)
Study: 19307466
Drug: Lisinopril/spironolactone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril/spironolactone (40 mg lisinopril/25 mg spironolactone)
Study: 17589899
Drug: Body awareness
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body awareness therapy (2 hours weekly for 24 weeks)
Study: 17589899
Drug: Body awareness
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body awareness therapy
Study: 11120401
Drug: Psychotherapeutic interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychotherapeutic interventions related to pharmacotherapy treatment adherence
Study: 11120401
Drug: Pharmacologic measures
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic measures of medication adherence
Study: 11120401
Drug: Treatment adherence
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment adherence interventions scale ratings
Study: 1926651
Drug: Fosfomycin trometamol
Normalized name: trometamol
DrugBank: Tromethamine (DB03754)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosfomycin trometamol (Monuril), 3-gram single dose
Study: 1926651
Drug: Norfloxacin (Noroxine),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (Noroxine), 400 mg twice daily for 5 days
Study: 31956037
Drug: Intensified platinum-based
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified platinum-based chemotherapy
Study: 31291055
Drug: Initial mild
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial mild to moderate daily GER
Study: 27078989
Drug: Shenyi Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenyi Capsule + Modified Yiqi Chutan Recipe (MYCR) + chemotherapy
Study: 27078989
Drug: Shenyi Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenyi Capsule + MYCR + chemotherapy
Study: 24262291
Drug: Insulin-stimulation after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-stimulation after high-fat overfeeding
Study: 22128078
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg subcutaneously every two weeks for 12 months
Study: 21156950
Drug: Protective ventilatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protective ventilatory strategy (tidal volumes of 6‐8 mL/kg, PEEP of 8‐10 cm H(2)O)
Study: 21156950
Drug: Conventional ventilatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional ventilatory strategy (tidal volumes of 10‐12 mL/kg, PEEP of 3‐5 cm H(2)O)
Study: 16330984
Drug: Warfarin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin therapy for 6 weeks after negative venograms
Study: 3533272
Drug: Tizanidine (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tizanidine (maximum daily dose 18 mg)
Study: 3533272
Drug: Carbamazepine (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (maximum daily dose 900 mg)
Study: 18561584
Drug: Once-daily azelaic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily azelaic acid 15% gel
Study: 18561584
Drug: Twice-daily azelaic
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily azelaic acid 15% gel
Study: 8685201
Drug: Tianeptine 25
Normalized name: tianeptine
DrugBank: Tianeptine (DB09289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tianeptine 25 mg/day
Study: 8685201
Drug: Mianserin 30
Normalized name: mianserin 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin 30 mg/day
Study: 8685201
Drug: Tianeptine 37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tianeptine 37.5 mg
Study: 24686107
Drug: Glucose-insulin-potassium (GIK)
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-insulin-potassium (GIK) administered in ambulances
Study: 16216096
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment, group C)
Study: 12011122
Drug: rituximab 375
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: rituximab 375 mg/m2 IV weekly for four doses (n = 70)
Study: 9892509
Drug: Intravenous prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous prostaglandin E1 (15 microg i.v. over 30 min)
Study: 2551907
Drug: Intravenous polymyxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous polymyxin B during the first week after burn injury
Study: 61952
Drug: FZ. 560
Approvals — FDA: no, EMA: no, PMDA: no
Description: FZ. 560 (combination of fentonium bromide 10 mg, dehydrocholic acid 25 mg, pancreatin 50 mg, lactulose 200 mg)
Study: 61952
Drug: Fentonium bromide
Normalized name: Potassium Bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentonium bromide 10 mg (control group)
Study: 29084409
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (reference medicine)
Study: 26416999
Drug: Epirubicin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin plus cyclophosphamide followed by docetaxel (EC-T; 90 mg/m2 epirubicin, 600 mg/m2 cyclophosphamide, 100 mg/m2 docetaxel)
Study: 26416999
Drug: Epirubicin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin plus docetaxel followed by capecitabine (ET-X; 90 mg/m2 epirubicin, 75 mg/m2 docetaxel, 1250 mg/m2 capecitabine)
Study: 15986587
Drug: Etiology of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etiology of CL (e.g., alcoholism)
Study: 12701670
Drug: Medication and
Normalized name: CVS Health Medication and Topical Refill Pouch KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication and placebo (control group)
Study: 7019930
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg tiaprofenic acid given 3-times daily for 7 days
Study: 7019930
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg aspirin given 3-times daily for 7 days
Study: 29040445
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg b.i.d. ticagrelor
Study: 29040445
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg b.i.d. ticagrelor
Study: 26395889
Drug: Topiramate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (100 or 200 mg)
Study: 8673548
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal treatment (31 Chinese herbs), 28 tablets each day
Study: 8673548
Drug: Placebo (cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (cellulose placebo), 28 tablets each day
Study: 1890532
Drug: 1.25% AmF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25% AmF gel
Study: 1890532
Drug: 0.4% F
Normalized name: Zest Overdenture 0.4% Fluoride Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4% F gel
Study: 1890532
Drug: 0% F
Normalized name: UREA 30% FOAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0% F gel
Study: 1890532
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups during 6-month discontinuation
Study: 6311009
Drug: Tobramycin or
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin or other comparative agents
Study: 29342199
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose metformin (375 mg followed by 250 mg)
Study: 29342199
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose metformin (1000 mg followed by 1000 mg)
Study: 29342199
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of metformin
Study: 26774115
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12 (500 μg) and folic acid (400 μg)
Study: 24815501
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment in the same center
Study: 21971437
Drug: Intramuscular Tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular Tramadol (Group TIM)
Study: 20646181
Drug: Fluoxetine (20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20mg qd)
Study: 17565489
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg rosiglitazone
Study: 16485509
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy intervention (not specified in detail)
Study: 16485509
Drug: Medications (antiparkinsonian
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications (antiparkinsonian drugs)
Study: 7389323
Drug: Topical idoxuridine
Normalized name: Idoxuridine
DrugBank: Idoxuridine (DB00249)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical idoxuridine 0.5% and 5% in petrolatum
Study: 7389323
Drug: Topical idoxuridine
Normalized name: Idoxuridine
DrugBank: Idoxuridine (DB00249)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical idoxuridine 5‐40% in dimethylsulfoxide (previous treatment)
Study: 21917635
Drug: Intrinsically l‐[1‐(13)C]phenylalanine‐labeled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrinsically l‐[1‐(13)C]phenylalanine‐labeled casein protein (PRO)
Study: 19116389
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (500 mg of ascorbic acid daily)
Study: 17324218
Drug: Intracameral mydriatics
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intracameral mydriatics (ICMs) with 0.6 microg/ml epinephrine
Study: 17324218
Drug: Topical mydriatics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical mydriatics (TMs) with 0.6 microg/ml epinephrine
Study: 17324218
Drug: Topical mydriatics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical mydriatics (TMs) without epinephrine
Study: 14717965
Drug: SanOrg34006 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SanOrg34006 2.5 mg
Study: 14717965
Drug: SanOrg34006 (5.0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SanOrg34006 (5.0, 7.5, 10 mg)
Study: 14717965
Drug: Warfarin (INR,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (INR, 2.0-3.0)
Study: 14717965
Drug: SanOrg34006 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: SanOrg34006 (all doses)
Study: 9675647
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.i.d., clarithromycin 500 mg b.i.d., and amoxycillin 1000 mg b.i.d. for one week
Study: 9675647
Drug: Tinidazole 500
Normalized name: tinidazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole 500 mg b.i.d. for one week
Study: 9675647
Drug: Pre-treatment Delta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment Delta Over Baseline at 30' value
Study: 9675647
Drug: Pre- and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre- and post-treatment Delta Over Baseline at 30' values
Study: 25388940
Drug: CT-322 monotherapy
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-322 monotherapy at 1 mg/kg IV weekly
Study: 25388940
Drug: CT-322 monotherapy
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-322 monotherapy at 2 mg/kg IV weekly
Study: 23596812
Drug: Fuzhengliqi mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuzhengliqi mixture (FLM) 60 mL twice a day
Study: 23596812
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at acupoints Tianshu (ST 25), Shangjuxu (ST 37), Zusanli (ST 36), Dachangshu (BL 25), and Zhigou (TE 6) twice a day
Study: 23596812
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with FLM and acupuncture
Study: 23596812
Drug: Mosapride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride (5 mg thrice a day) and Macrogol 4000 (10 g twice a day)
Study: 19349340
Drug: Community-based rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based rehabilitation therapy for five months
Study: 19349340
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no additional rehabilitation therapy)
Study: 16193299
Drug: 200 IU
Normalized name: Vitamin E 200 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 IU intranasal salmon calcitonin and 1,000 mg of oral calcium daily (groups IA, IIA, IIIA)
Study: 16193299
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg of oral calcium daily (groups IB, IIB, IIIB)
Study: 15130257
Drug: Doxycycline therapy
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline therapy (100 mg)
Study: 15130257
Drug: Inpatient and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient and outpatient treatment groups
Study: 11524318
Drug: Target-controlled infusion
Normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Target-controlled infusion (TCI) Propofol
Study: 9239772
Drug: Inactivated poliovirus
Normalized name: Inactivated poliovirus type I
DrugBank: Poliovirus type 1 antigen (formaldehyde inactivated) (DB10795)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated poliovirus vaccine (IPV) or oral poliovirus vaccine (OPV)
Study: 9239772
Drug: COMVAX (Hib
Approvals — FDA: no, EMA: no, PMDA: no
Description: COMVAX (Hib and hepatitis B vaccine)
Study: 29692602
Drug: Rosuvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (20 mg) alone
Study: 29692602
Drug: Ezetimibe (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe (10 mg) alone
Study: 29692602
Drug: Rosuvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (20 mg) plus Ezetimibe (10 mg)
Study: 28715142
Drug: Pyridostigmine (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (45 mg, 3 times/day)
Study: 18466210
Drug: Four daily
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four daily insulin injections
Study: 17144454
Drug: PYM emulsion
Normalized name: propofol lipid emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: PYM emulsion applied 3 times daily on the lesions
Study: 12725542
Drug: Once-daily (OD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily (OD) gentamicin 5 mg kg(‐1) d(‐1)
Study: 12725542
Drug: Conventional 8-hourly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional 8-hourly dosing (TDS) gentamicin 6 mg kg(‐1) d(‐1)
Study: 3995516
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 40 mg ISDSR
Study: 3995516
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of 40 mg ISDSR (at 07.30 and 13.30 h)
Study: 31250602
Drug: Intermittent negative
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent negative pressure therapy (20 minutes, 5 times per week for 4 weeks)
Study: 26808136
Drug: Aspirin (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (81 mg or 100 mg daily)
Study: 22742538
Drug: Immediate antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate antibiotic therapy with fosfomycin-trometamol 1x3g
Study: 22742538
Drug: Initial symptomatic
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial symptomatic treatment with ibuprofen 3x400mg for 3 days
Study: 21063142
Drug: Limited intraoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limited intraoperative hydration (no more than 1500 ml in the first 2 hours)
Study: 16279901
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy with lamivudine 100 mg per day for 52 weeks and IFN 5 MIU per day for 16 weeks after the first 8 weeks (group A)
Study: 16279901
Drug: Lamivudine monotherapy
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine monotherapy 100 mg per day for 52 weeks (group B)
Study: 16885196
Drug: TNFA (‐308
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNFA (‐308 G>A) polymorphism
Study: 16885196
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IFNGR2 Ex7‐128 C/C and TNFA ‐308 A/A genotypes
Study: 6388070
Drug: anti-T3 antibody
Normalized name: Anti-T3 antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-T3 antibody (5 mg i.v./day for 14 days)
Study: 6388070
Drug: steroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: steroid treatment
Study: 6388070
Drug: anti-T3 antibody
Normalized name: Anti-T3 antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-T3 antibody
Study: 29595751
Drug: Additional information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional information provided for recommended precancer treatment
Study: 22167563
Drug: Romiplostim (subcutaneous,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romiplostim (subcutaneous, dose range 0.2‐10 µg/kg)
Study: 15691277
Drug: ATG induction
Normalized name: ATGAM Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG induction therapy
Study: 10721643
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg thrice a day for three days, starting one hour prior to angiography)
Study: 10721643
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg thrice a day for three days)
Study: 28451442
Drug: Single steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single steroid injection (followed by later surgery if required)
Study: 23324512
Drug: Pharmacist intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist intervention (complete medication history, limited physical examination, provision of guideline-concordant recommendations, and 1-year follow-up)
Study: 12880499
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sertraline and CBT
Study: 10642897
Drug: Multivitamin/mineral supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin/mineral supplementation (one tablet daily for 10 weeks)
Study: 8895156
Drug: N‐3 fatty
Approvals — FDA: no, EMA: no, PMDA: no
Description: N‐3 fatty acids (fish oil) 8 g for 16 weeks
Study: 6828277
Drug: Ampicillin (2-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin (2-g dose administered intravenously)
Study: 30121944
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) treatment for 3 weeks during neonatal care
Study: 27306517
Drug: Chemotherapy (platinum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (platinum and pemetrexed) in combination with erlotinib